The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The role of selinexor in DLBCL and the challenges of implementing this agent in patients
Tycel Phillips, MD, City of Hope, Duarte, CA, comments on the role of selinexor in diffuse large B-cell lymphoma (DLBCL), highlighting the adverse events (AEs) associated with this agent and the challenges of implementing it in this patient population. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
